SAB Biotherapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $282.9M
- Price
- $3.70
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.12%
- Volume
- 229.6K
About
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Quick stats
Shares outstanding76.5M
Computed float68.3M
Float / shares89.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001833214
AI Summary
AI-generated1/12
standardbullishearnings
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
SAB Biotherapeutics reported a cash position of $208.0 million at the end of Q2 2026, providing an operational runway through 2028. The company posted a net loss of $22.5 million for the quarter, driven by increased R&D expenses of $16.2 million to support the advancement of its SAB-142 program.
Clinical development continues on schedule, with over 60 sites activated and enrollment on track for completion in Q4 2026 for the registrational SAFEGUARD study. The Phase 3 PRISE-hATG study also received a grant from Breakthrough T1D to evaluate SAB-142 in patients up to two years from diagnosis.
Operationally, SAB BIO began construction of a second farm facility to secure long-term commercial supply and was added to the Russell 3000 and Russell 2000 indexes in June.